Merck’s MRKshares increased 2.59% on Apr 16 after it presented full data from the pivotal phase III KEYNOTE-189 study. Data from the same showed that Keytruda combined with Eli Lilly’s LLYAlimta (pemetrexed) and platinum chemotherapy (cisplatin or carboplatin) significantly improved overall survival, thereby reducing the death risk by half (51%) compared with chemotherapy alone.
Merck's Keytruda Betters Survival in Lung Cancer Combo Study
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться